Literature DB >> 32442541

Association of CASP8 polymorphisms and cancer susceptibility: A meta-analysis.

Mohammad Hashemi1, Sajjad Aftabi2, Abdolkarim Moazeni-Roodi3, Hosna Sarani4, Emilia Wiechec5, Saeid Ghavami6.   

Abstract

Caspase-8 plays is an essential enzyme in apoptosis pathway. Several investigation have been done to identify the relation between CASP8 polymorphisms and different human cancers, but, the findings are still debated. The aim of the current investigation is to assess if CASP8 rs3834129 (-652 6N insertion/deletion), rs1045485 G > C, rs3769818 G > A, rs6723097 A > C, rs3769821 T > C, rs13113 T > A, rs3769825 G > A, rs2293554 A > C, and rs10931936 C > T polymorphisms are linked to susceptibility of cancer. Our team has extracted the eligible studies up to July 4, 2019, from different sources. Pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were estimated to quantitatively evaluate the association between CASP8 polymorphisms and cancer susceptibility. Our results showed that the rs3834129 and rs1045485 polymorphisms meaningfully reduced the risk of cancer, while the rs3769818, rs3769821 and rs3769825 polymorphisms considerably increased cancer susceptibility. No association of rs6723097, rs13113, rs2293554 and rs10931936 polymorphisms was observed with cancer susceptibility. The CASP8 rs3834129 polymorphism reduced the risk of gastrointestinal, digestive tract, colorectal, breast and lung cancers. Furthermore, the cancer risk was decreased in Asian and Caucasian populations as well as population- and hospital-based studies due to this polymorphism. There was not any relation between this gene polymorphism and the risk of prostate and cervical cancer development. Regarding the CASP8 rs1045485 polymorphism, the reduced breast cancer risk along with the risk of cancer in Caucasians, population- and hospital-based studies were observed.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CASP8; Cancer; Meta-analysis; Polymorphism

Mesh:

Substances:

Year:  2020        PMID: 32442541     DOI: 10.1016/j.ejphar.2020.173201

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer.

Authors:  Xu Zhang; Na Qin; Jingyi Fan; Chang Zhang; Qi Sun; Yayun Gu; Meng Zhu; Erbao Zhang; Juncheng Dai; Guangfu Jin; Hongxia Ma; Zhibin Hu; Hongbing Shen
Journal:  Cancer Biol Med       Date:  2022-09-02       Impact factor: 5.347

2.  The Search for Cancer Biomarkers: Assessing the Distribution of INDEL Markers in Different Genetic Ancestries.

Authors:  Roberta B Andrade; Giovanna C Cavalcante; Marcos A T Amador; Fabiano Cordeiro Moreira; André S Khayat; Paulo P Assumpção; Ândrea Ribeiro-Dos-Santos; Ney P C Santos; Sidney Santos
Journal:  Curr Issues Mol Biol       Date:  2022-05-19       Impact factor: 2.976

3.  A newly identified pyroptosis-related gene signature for predicting prognosis of patients with hepatocellular cancer.

Authors:  Qinyan Shen; Yangping Jiang; Xihong Hu; Zhenwu Du
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

4.  Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women.

Authors:  Shima Karami; Hedieh Sattarifard; Mohammad Kiumarsi; Sahel Sarabandi; Mohsen Taheri; Mohammad Hashemi; Gholamreza Bahari; Saeid Ghavami
Journal:  Asian Pac J Cancer Prev       Date:  2020-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.